FDA Unwilling To Change View On Dangers Of Zicam

By Julie Zeveloff

Law360, New York (October 26, 2009, 1:41 PM ET) -- The maker of Zicam, a cold medication that has come under fire in recent months for its potential danger to consumers, has said in a regulatory filing that the U.S. Food and Drug Administration is unwilling to reverse its stance that the medication could cause users to lose their sense of smell.

Matrixx Initiatives Inc., which makes Zicam, disclosed in an 8K filing with the U.S. Securities and Exchange Commission Monday that the FDA was unlikely to change the position it took in a warning letter...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles